Literature DB >> 15240709

Role of IFN regulatory factor-1 and IL-12 in immunological resistance to pathogenesis of N-methyl-N-nitrosourea-induced T lymphoma.

Jianguo Liu1, Zhaoying Xiang, Xiaojing Ma.   

Abstract

IFN regulatory factor-1 (IRF-1) is a critical effector molecule in IFN signaling and acts as a tumor suppressor and tumor susceptibility gene. IL-12 is a key factor in the induction of innate resistance and generation of Th1 cells and CTL. Our recent study has revealed an intimate relationship between IRF-1 and IL-12 in that IRF-1 regulates the production of IL-12 by selectively controlling transcriptional activation of IL-12 p35 gene. In this work, we find that IRF-1-deficient mice are highly susceptible to N-methyl-N-nitrosourea (MNU)-induced T lymphomas. This susceptibility is associated with strong defects in the expression of IL-12, lymphotoxin (LT)beta, and IFN-gamma. Consistently, IL-12 p35(-/-), IFN-gamma(-/-), and LTbeta(-/-) mice are also highly vulnerable to MNU-induced carcinogenesis. Administration of rIL-12 to IRF-1(-/-) mice restores normal expression of LTbeta and IFN-gamma, and significantly enhances the ability of IRF-1(-/-) mice to resist MNU-induced pathogenesis. This strongly suggests an IRF-1/IL-12/IFN-gamma regulatory axis in tumor surveillance. By DNA microarray analysis, we comprehensively identify differences and patterns in gene expression in splenocytes of wild-type (WT) vs IRF-1(-/-) mice challenged with MNU. This study contributes to efforts to elucidate the cellular/molecular mechanisms and the downstream players involved in IRF-1-mediated host defense against lymphoproliferative malignancies.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15240709     DOI: 10.4049/jimmunol.173.2.1184

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  11 in total

Review 1.  Interleukin (IL)-12 and IL-23 and Their Conflicting Roles in Cancer.

Authors:  Juming Yan; Mark J Smyth; Michele W L Teng
Journal:  Cold Spring Harb Perspect Biol       Date:  2018-07-02       Impact factor: 10.005

2.  Intratumoral Plasmid IL12 Electroporation Therapy in Patients with Advanced Melanoma Induces Systemic and Intratumoral T-cell Responses.

Authors:  Samantha K Greaney; Alain P Algazi; Katy K Tsai; Kathryn T Takamura; Lawrence Chen; Christopher G Twitty; Li Zhang; Alan Paciorek; Robert H Pierce; Mai H Le; Adil I Daud; Lawrence Fong
Journal:  Cancer Immunol Res       Date:  2019-12-18       Impact factor: 11.151

3.  Methylation-independent repression of Dnmt3b contributes to oncogenic activity of Dnmt3a in mouse MYC-induced T-cell lymphomagenesis.

Authors:  Staci L Haney; Ryan A Hlady; Jana Opavska; David Klinkebiel; Samuel J Pirruccello; Samikshan Dutta; Kaustubh Datta; Melanie A Simpson; Lizhao Wu; Rene Opavsky
Journal:  Oncogene       Date:  2015-02-02       Impact factor: 9.867

Review 4.  New insights into IL-12-mediated tumor suppression.

Authors:  S Tugues; S H Burkhard; I Ohs; M Vrohlings; K Nussbaum; J Vom Berg; P Kulig; B Becher
Journal:  Cell Death Differ       Date:  2014-09-05       Impact factor: 15.828

Review 5.  Tissue-resident cytotoxic innate lymphoid cells in tumor immunosurveillance.

Authors:  Efstathios G Stamatiades; Ming O Li
Journal:  Semin Immunol       Date:  2019-03-21       Impact factor: 11.130

Review 6.  Immune surveillance of tumors.

Authors:  Jeremy B Swann; Mark J Smyth
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

Review 7.  Cytotoxic T cells in H. pylori-related gastric autoimmunity and gastric lymphoma.

Authors:  Mathijs P Bergman; Mario M D'Elios
Journal:  J Biomed Biotechnol       Date:  2010-06-22

8.  Enhanced Susceptibility of Ogg1 Mutant Mice to Multiorgan Carcinogenesis.

Authors:  Anna Kakehashi; Naomi Ishii; Takahiro Okuno; Masaki Fujioka; Min Gi; Hideki Wanibuchi
Journal:  Int J Mol Sci       Date:  2017-08-18       Impact factor: 5.923

Review 9.  Single-Cell Approaches to Profile the Response to Immune Checkpoint Inhibitors.

Authors:  Lara Gibellini; Sara De Biasi; Camillo Porta; Domenico Lo Tartaro; Roberta Depenni; Giovanni Pellacani; Roberto Sabbatini; Andrea Cossarizza
Journal:  Front Immunol       Date:  2020-03-20       Impact factor: 7.561

10.  Type 1 conventional dendritic cells and interferons are required for spontaneous CD4+ and CD8+ T-cell protective responses to breast cancer.

Authors:  Raphaël Mattiuz; Carine Brousse; Marc Ambrosini; Jean-Charles Cancel; Gilles Bessou; Julie Mussard; Amélien Sanlaville; Christophe Caux; Nathalie Bendriss-Vermare; Jenny Valladeau-Guilemond; Marc Dalod; Karine Crozat
Journal:  Clin Transl Immunology       Date:  2021-07-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.